ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 2856 • 2014 ACR/ARHP Annual Meeting

    Update on Long-Term Outcomes after Reversible Cerebral Vasoconstriction Syndrome (RCVS)

    Seby John1, Aneesh Singhal2, Leonard H. Calabrese3, Ken Uchino4, Tariq Hammad3, Stewart Tepper3, Mark Stillman3 and Rula A Hajj-Ali5, 19500 Euclid Avenue S10-C, Cleveland Clinic Foundation, Cleveland, OH, 2Neurology, Massachusetts General Hospital, Boston, MA, 3Cleveland Clinic Foundation, Cleveland, OH, 4Neurology, Cleveland Clinic Foundation, Cleveland, OH, 5Rheumatology, Cleveland Clinic Foundation, Cleveland, OH

    Background/Purpose RCVS is characterized by acute onset of severe headaches, with or without neurologic deficit with evidence of reversible cerebral vasoconstriction. We have previously reported…
  • Abstract Number: 2857 • 2014 ACR/ARHP Annual Meeting

    Restricting Back Pain Is Strongly Associated with Disability in Community-Living Older Persons over the Course of 13 Years

    Una Makris1,2, Liana Fraenkel3, Ling Han4, Linda Leo-Summers4 and Thomas M. Gill5, 1Rheumatology, UT Southwestern Medical Center, Dallas, UT, 2Rheumatology, Dallas VA Medical Ctr, Dallas, TX, 3Rheumatology, Yale University School of Medicine, Veterans Affairs Connecticut Healthcare Systems, New Haven, CT, 4Internal Medicine, Department of Medicine, New Haven, CT, 5Internal Medicine, Section of Geriatrics, Yale University, New Haven, CT

    Background/Purpose: Although back pain is common and costly, few longitudinal studies have evaluated the association between back pain severe enough to restrict activity [hereafter referred…
  • Abstract Number: 2858 • 2014 ACR/ARHP Annual Meeting

    Education Effects on Outcome Expectations for Exercise in Adults with Knee Osteoarthritis

    Tressa Gamache1, Lori Lyn Price2, Jeffrey B. Driban1, William F. Harvey1 and Chenchen Wang1, 1Rheumatology, Tufts Medical Center, Boston, MA, 2Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA

    Background/Purpose Outside of a clinical trial setting, higher outcome expectations for exercise, more education, and greater physical activity are inter-related, and outcome expectations may partly…
  • Abstract Number: 2859 • 2014 ACR/ARHP Annual Meeting

    Randomized Controlled Trial of Postoperative Care Navigation in Total Knee Arthroplasty Patients: Does One Size Fit All?

    Elena Losina1, Jamie E. Collins1, John Wright2, Meghan E. Daigle1, Laurel Donnell-Fink3, Doris Strnad2, Vladislav Lerner1, Stanley Abrams4 and Jeffrey N. Katz5, 1Orthopaedic and Arthritis Center for Outcomes Research, Brigham and Women's Hospital, Boston, MA, 2Orthopaedics, Brigham and Women's Hospital, Boston, MA, 3Brigham and Women's Hospital, Boston, MA, 4Orthopedics and Arthritis Center for Outcomes Research, Brigham and Women's Hospital, Boston, MA, 5Rheumatology and Orthopedics, Brigham and Women's Hospital, Boston, MA

    Background/Purpose: A number of TKA recipients have suboptimal improvements after surgery. Our objective was to establish the efficacy of a motivational-interviewing (MI)-based telephone intervention aimed…
  • Abstract Number: 2860 • 2014 ACR/ARHP Annual Meeting

    Randomised Comparison of the Effectiveness of a Non-Pharmacological Multidisciplinary Face-to-Face Group-Based Treatment Program Vs. a Telephone-Delivered Treatment Program on Daily Function in Patients with Generalized Osteoarthritis

    Nienke Cuperus1, Thomas Hoogeboom2, Clarinda Kersten3, Leonie Rietveld4, Alfons den Broeder4, Thea Vliet Vlieland5 and Cornelia H.M. van den Ende4, 1Rheumatology Department, Sint Maartenskliniek, Nijmegen, Netherlands, 2Department of Epidemiology, CAPHRI school for public health and primary care, CCTR centre for Care Technology Research, Maastricht University, Maastricht, Netherlands, 3Department of Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, 4Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, 5Dept of Orthopaedics, Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: Generalized osteoarthritis (GOA) is a widely accepted and prevalent OA phenotype characterized by the involvement of multiple joints. However, current research and clinical practice…
  • Abstract Number: 2861 • 2014 ACR/ARHP Annual Meeting

    Changes in Knee Kinematics from a 6-Week Hip and Trunk Strengthening Program for Persons with Patellofemoral Osteoarthritis

    Lisa Hoglund1, Laura Pontiggia2, John Kelly IV3, Mark Arnott4, Olumide Babalola4, Andrew Gushen4 and James Carey3, 1Department of Physical Therapy, University of the Sciences, Philadelphia, PA, 2Mathematics, Physics, and Statistics, University of the Sciences, Philadelphia, PA, 3Orthopaedic Surgery, University of Pennsylvania, Philadelphia, PA, 4Physical Therapy, University of the Sciences, Philadelphia, PA

    Background/Purpose: Patellofemoral (PF) osteoarthritis (OA) is prevalent in middle-aged adults. Aberrant lower extremity (LE) biomechanics is one etiology of knee OA. Reduced peak knee flexion…
  • Abstract Number: 2862 • 2014 ACR/ARHP Annual Meeting

    Satisfaction Following Total Knee Replacement: Journey or Destination?

    Jeffrey N. Katz1, Yan Dong2, Jamie E. Collins2, John Wright3, David Dalury4, Kirk Kindsfater5 and Elena Losina2, 1Rheumatology and Orthopedics, Brigham and Women's Hospital, Boston, MA, 2Orthopaedic and Arthritis Center for Outcomes Research, Brigham and Women's Hospital, Boston, MA, 3Orthopedic Surgery, Brigham and Women's Hospital, Boston, MA, 4Townson Orthopedics, Maryland, Baltimore, MD, 5Orthopedic Center for the Rockies, Ft. Collins, CO

    Background/Purpose: Total knee replacement (TKR) outcome is often assessed with measures of pain and function (fxn), but there is no consensus on whether surgery should…
  • Abstract Number: 2863 • 2014 ACR/ARHP Annual Meeting

    IgG Antiphospholipid Antibodies Enhance Stroke Damage: An in Vivo Ischemia/Reperfusion Study

    Charis Pericleous1, Valerie Taylor2, Lauren Bourke3, Daniel Stuckey2, Jed Wingrove4, Mark Lythgoe5, Silvia S. Pierangeli6, Anisur Rahman3, Ian Giles1 and Yiannis Ioannou7, 1Centre for Rheumatology, Division of Medicine, Centre for Rheumatology, University College London, London, United Kingdom, 2Centre for Advanced Biomedical Imaging (CABI), University College London, London, United Kingdom, 3Centre for Rheumatology Research, University College London, London, United Kingdom, 4Centre for Advanced Biomedical Imaging, University College London, London, United Kingdom, 5Centre for Advanced Biomedical Imaging, Centre for Advanced Biomedical Imaging (CABI), University College London, London, United Kingdom, 6Rheumatology/Dept Int Med, University of Texas Medical Branch, Galveston, TX, 7Centre for Rheumatology Research, University College Hospital London, London, United Kingdom

    Background/Purpose Circulating pathogenic antiphospholipid antibodies (aPL) are the hallmark of antiphospholipid syndrome (APS) and a major risk factor for ischemic stroke, with up to one…
  • Abstract Number: 2864 • 2014 ACR/ARHP Annual Meeting

    Markers of Thrombotic Events in Autoimmune Diseases:Comparison of Antiphospholipid Score (aPL-S) and Global Anti-Phospholipid Syndrome Score (GAPSS)

    Kenji Oku, Olga Amengual, Ryo Hisada, Kazumasa Oomura, Ikuma Nakagawa, Toshiyuki Watanabe, Toshiyuki Bohgaki, Tetsuya Horita, Shinsuke Yasuda and Tatsuya Atsumi, Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan

    Background/Purpose Recently, new scoring systems to quantify the probability for the diagnosis of antiphospholipid syndrome (APS) have been proposed in sequence: the Antiphospholipid Score(aPL-S) and…
  • Abstract Number: 2865 • 2014 ACR/ARHP Annual Meeting

    The Cellular Effects of ANTI-Factor Xa Antibodies Isolated from Patients with Antiphospholipid Syndrome ARE Inhibited By Factorxa Inhibitors, Hydroxychloroquine and Fluvastatin

    Bahar Artim-Esen1, Natalia Smoktunowicz2, Vera M. Ripoll3, Charis Pericleous4, Rachel Chambers2, Ian Mackie5, David Isenberg6, Anisur Rahman7, Yiannis Ioannou6 and Ian Giles4, 1Department of Internal Medicine, Division of Rheumatology, Rheumatology Division, Department of Internal Medicine, Istanbul Faculty of Medicine,Istanbul University, Istanbul, Turkey, 2Rayne Institute, 1st floor, Respiratory Research Unit, University College London, London, United Kingdom, 3Centre for Rheumatology, Rayne Institute, 4th floor, Centre for Rheumatology, University College London, London, United Kingdom, 4Centre for Rheumatology, Division of Medicine, Centre for Rheumatology, University College London, London, United Kingdom, 5Haemostasis Research Unit, 1st Floor, 51 Chenies Mews, Haemostasis Research Unit, University College London, London, United Kingdom, 6Centre for Rheumatology Research, University College Hospital London, London, United Kingdom, 7Centre for Rheumatology Research, University College London, London, United Kingdom

    Background/Purpose Recently we showed that FXa reactive IgG in patients with the antiphospholipid syndrome (APS) displayed higher avidity binding to FXa and had greater functional…
  • Abstract Number: 2866 • 2014 ACR/ARHP Annual Meeting

    External Validation of the Global Anti-Phospholipid Syndrome Score in Comparison to IgG Antibodies Directed Against Domain I of ß2-Glycoprotein I. a Prospective Multicentre Cohort Study

    Stephane Zuily1, Bas De Laat2, Veronique Regnault3, Pierre Kaminsky4, Hilde Kelchtermans5, Zakera Shums6, Roger Albesa7, Gary L Norman6, Philip de Groot8, Anne-Christine Rat9, Jacques Ninet10, Nadine Magy-Bertrand11, Jean-Louis Pasquali12, Marc Lambert13, Bernard Lorcerie14, Thomas Lecompte15, Francis Guillemin16 and Denis Wahl17, 1CHU de Nancy, Vascular Medicine Division and Regional Competence Center For Rare Vascular And Systemic Autoimmune Diseases, Nancy, F-54000, France; Inserm, UMR_S 1116, Nancy, F-54000, France; Université de Lorraine, Nancy, F-54000, France, Nancy, France, 2Biochemistry, CARIM, Maastricht University, Maastricht, Netherlands, 3Inserm, UMR_S 1116, Nancy, F-54000, France; Université de Lorraine, Nancy, F-54000, France; CHU de Nancy, Contrat d’interface, Nancy, F-54000, France, Nancy, France, 4Internal Medicine, CHU Nancy, Vandoeuvre, France, 5Biochemistry, CARIM, Maastricht University, The Netherlands; Synapse BV, Maastricht, The Netherlands, Maastricht, Netherlands, 6INOVA Diagnostics, San Diego, CA, 7Research, INOVA Diagnostics, San Diego, CA, 8Clinical Chemistry and Hematology, UMC Utrecht, The Netherlands, Utrecht, Netherlands, 9University Paris Descartes, EA 4360 APEMAC, University of Lorraine, Nancy, France, 10Department of Nephrology and Internal Medicine, Hôpital Edouard Herriot, Lyon, France, Lyon, France, 11Bensançon University Hospital, Besançon, France, 12Service de Medecine Interne, Nouvel Hospital Civil, Strasbourg Cedex, France, 13Lille University Hospital, Lille, France, 14Hopital Du Bocage, Service de Médecine Interne et Immunologie Clinique, Dijon, France, 15Inserm, UMR_S 1116, Nancy, F-54000, France; Université de Lorraine, Nancy, F-54000, France; CHU de Nancy, Haematology Laboratory, Nancy, F-54000, France; Division of Haematology, HUG, Geneva, Switzerland (current address), Geneva, Switzerland, 16INSERM, Centre d'Investigation Clinique - Epidémiologie Clinique (CIC-EC) CIE6, Nancy, France, 17Regional Competence Center For Rare Vascular And Systemic Autoimmune Diseases, Nancy University Hospital and INSERM U961, Vandoeuvre-Les-Nancy, France

    Background/Purpose: Our objectives were 1- to perform an external validation of the Global Anti-Phospholipid Syndrome Score (GAPSS) and 2- to compare prognostic significances of GAPPS…
  • Abstract Number: 2867 • 2014 ACR/ARHP Annual Meeting

    Antiphospholipid Antibodies Promote the Release of Neutrophil Extracellular Traps:  a New Mechanism of Thrombosis in the Antiphospholipid Syndrome

    Srilakshmi Yalavarthi1, Levi F. Mazza1, Alexandra E. Morris1, Carlos Núñez-Álvarez2, Diego Hernández2, Paula L. Bockenstedt3, Antonio R. Cabral4 and Jason S. Knight1, 1Department of Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI, 2Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico, 3Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI, 4Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico

    Background/Purpose:  Antiphospholipid antibodies (aPL), especially those targeting beta-2-glycoprotein I, are known to activate endothelial cells, monocytes, and platelets, with prothrombotic implications.  However, the interaction of…
  • Abstract Number: 2868 • 2014 ACR/ARHP Annual Meeting

    Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository Initial Analysis

    Doruk Erkan1, Danieli Andrade2, Maria Tektonidou3, Amaia Ugarte4, Alessandra Banzato5, Angela Tincani6, Pier-Luigi Meroni7, Ricard Cervera8, Paul R. Fortin9, Roger A. Levy10 and On Behalf of APS Action11, 1Rheumatology, Hospital for Special Surgery, New York, NY, 2Rheumatology, University of São Paulo, São Paulo, Brazil, 3First Department of Internal Medicine, Laikon Hospital, Athens University Medical School, Athens, Greece, 4Hospital Universitario Cruces, Bizkaia, Spain, 5Department of Cardiac Thoracic and Vascular Sciences, Department of Cardiac Thoracic and Vascular Sciences, University of Padua, Padua, Italy, 6Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, 7Int Medicine, University of Milan, Milano, Italy, 8Hospital Clinic, Barcelona, Spain, 9Rheumatology, Laval University, Division of Rheumatology, Centre de Recherche du CHU de Québec and Department of Medicine, Quebec City, QC, Canada, 10Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, 11APS ACTION, New York, NY

    Background/Purpose: APS ACTION International Clinical Database and Repository (“Registry”) was created to study the natural course of disease over 10 years in persistently aPL-positive patients…
  • Abstract Number: 2869 • 2014 ACR/ARHP Annual Meeting

    TLR7 Influences Autoreactive B Cell Selection in the Germinal Center

    Weiqing Huang1, Megan Woods1, Alexis Boneparth2, Ramalingam Bethunaickan1, Ranjit Sahu1 and Anne Davidson1, 1Autoimmunity and Musculoskeletal Diseases, Feinstein Institute for Medical Research, Manhasset, NY, 2Pediatric Rheumatology, Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ

    Background/Purpose: TLR7 is required for the generation of anti-RNA antibodies and excess TLR7 confers a SLE-like phenotype in mice. Recent studies have shown that TLR7…
  • Abstract Number: 2870 • 2014 ACR/ARHP Annual Meeting

    B Cell-Intrinsic Deletion of the Type 1 Interferon Receptor Does Not Impact the Development of Murine Lupus

    Shaun W. Jackson1,2, Nicole Scharping1, Socheath Khim1 and David Rawlings1,2, 1Seattle Children's Research Institute, Seattle, WA, 2Pediatrics, University of Washington, Seattle, WA

    Background/Purpose Type 1 interferon (IFN) is strongly implicated in lupus pathogenesis, and patients with SLE frequently express a “type 1 IFN gene signature”. Type 1…
  • « Previous Page
  • 1
  • …
  • 2041
  • 2042
  • 2043
  • 2044
  • 2045
  • …
  • 2607
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology